3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Burkitt Lymphoma
9
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia
3
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Recurrence
1
Philadelphia Chromosome
1
Lymphoma, B-Cell
1
Interventions
Imatinib Mesylate
8
Dasatinib
4
Vincristine
3
Methotrexate
3
Dexamethasone
3
Cytarabine
3
peginterferon alfa-2a
2
Prednisone
2
Daunorubicin
2
Cyclophosphamide
2
venetoclax
1
ponatinib
1
olverembatinib
1
flumatinib
1
bosutinib
1
blinatumomab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mitoxantrone
1
Mercaptopurine
1
Interferons
1
Inotuzumab Ozogamicin
1
Etoposide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Philadelphia Chromosome
×
Inotuzumab Ozogamicin
×
Clear all
NCT03249870
2023-09-06
EWALL-INO
Versailles Hospital
Phase 2
Unknown
130 enrolled